Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $52.3 million.

  • Viridian Therapeutics, Inc.\DE's Net Cash Flow fell 4352.62% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 13456.94%. This contributed to the annual value of -$3.2 million for FY2024, which is 9387.13% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Net Cash Flow of $52.3 million as of Q3 2025, which was down 4352.62% from $1.1 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Net Cash Flow high stood at $312.9 million for Q3 2022, and its period low was -$188.6 million during Q4 2022.
  • Moreover, its 5-year median value for Net Cash Flow was $435000.0 (2022), whereas its average is $6.5 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Net Cash Flow soared by 2220119.28% in 2021 and then crashed by 203260.14% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Net Cash Flow (Quarter) stood at -$96.6 million in 2021, then plummeted by 95.32% to -$188.6 million in 2022, then soared by 95.35% to -$8.8 million in 2023, then tumbled by 1048.49% to -$100.7 million in 2024, then surged by 151.95% to $52.3 million in 2025.
  • Its Net Cash Flow stands at $52.3 million for Q3 2025, versus $1.1 million for Q2 2025 and $16.6 million for Q1 2025.